Ophthalmology, Pulmonary, Renal, and Reproductive Diseases Research at UMMS.
Research topics on Ophthalmology, Pulmonary, Renal, and Reproductive Diseases at UMMS includes:
Blindness and Corneal Diseases, Apnea, Cystic fibrosis, Emphysema, Smoking, Nephritis, Eclampsia/Preeclampsia, Polycystic ovarian syndrome, Premature birth, Premature ovarian aging, and more. Browse our innovation by scrolling though below.
Browse Our Ophthalmology, Pulmonary, Renal, and Reproductive Diseases Research Inventions:
Title: AAV2-mediated Gene Delivery of sFasL as a Neuroprotective Therapy in Glaucoma. UMMS16-64; Patent Pending.
New AAV therapy facilitates long-term production of sFasLin the retina by intra-vitreal injection with no detrimental effect observed in normal animals. Glaucoma-prone mice were injected either before or after disease onset and both animals were found to have preserved retinal ganglion cells with their axons, which normally results in death with onset of the disease.
Title: Systems and Methods for Monitoring, Managing, and Treating Asthma and Anaphylaxis. UMMS16-40; Patent Pending.
The invention describes two devices that enable outpatient monitoring of asthma severity and anaphylaxis in real time. The first device is a wearable device that monitors breathing, assesses asthma severity, and alerts to dangerous changes. The second device is a wearable device that alerts upon early detection of anaphylaxis, auto-injects epinephrine, and calls emergency services (e.g., initiates 911 call) and/or family. Both technologies.
Title: A Process for Delivering Small RNAs to Sperm. UMMS16-37; Patent Pending.
This invention provides methods to modulate transgenerational epigenetic inheritance, wherein some epigenetic phenotypes are maintained through generations. The disclosed method involves using epididymosomes, small vesicles found in the testis, to deliver RNA molecules to sperm, enabling tailored RNA delivery to the zygote upon fertilization.
Title: Development of Anti-angiogenic miRNA Therapeutics for Corneal Neovascularization. UMMS16-23; Patent Pending.
This new technology includes two novel inventions: 1) discovery of miRNAs that influences the neovascularization of the cornea and 2) optimization of rAAV gene therapy method for specific delivery to the cornea. Neovascularization is the most common corneal pathological condition and underestimated cause of blindness. Injection of the rAAV constructs that include synthetic nucleic acids that mimic or inhibit the discovered miRNA can reduce corneal neovascularization in mice.
Title: Identification of Epigenetic Modifiers of the Silenced FMR1 Gene: Potential Targets for Fragile X Syndrome Therapeutics. UMMS16-03; Patent Pending.
This invention comprises methods for treating Fragile X Syndrome and other FMR1-inactivation-associated disorders by inhibiting epigenetic silencers of the FMR1 gene. The invention discloses a variety of FMR1 modulators, functioning either through RNA interference or small molecule inhibition, for optimal FMR1 reactivation.
Title: SerpinA1 Null Mouse as a Model for Alpha-one Antitrypsin Deficiency and Lung Conditions. UMMS15-62. Patent Pending.
The invention provides a novel mouse model with alpha-one antitrypsin deficiency for use as a tool to study lung conditions including emphysema. With the use of the recently developed CRISPR technology, the inventors designed and implemented a strategy to delete all five copies of the SerpinA1 gene at once overcoming previous technical limitations preventing development of SerpinA1 null mice.
Title: New XCI Inhibitors as Potential Rett Syndrome Therapeutics. UMMS15-53; Patent Pending.
This invention provides methods of treating a subject having a dominant X-linked disease, the method comprising administering to the subject an X chromosome inactivation factor (XCIF) inhibitor in an amount effective for inducing expression a target X-linked gene. The invention provides small molecule and oligonucleotide XCIF inhibitors. In some embodiments, the X-linked gene is MECP2 and the X-linked disease is Rett Syndrome.
Title: Developing of Soluble FLT1 Targeting Therapeutics for Treatment of Preeclampsia. UMMS15-50; Patent Pending.
Selective elimination (filtration) of circulation "soluble fms-like tyrosine kinase 1" proteins (sFLT1s) in women with preeclampsia is a successful strategy for treatment of preeclampsia. The invention comprises oligonucleotide compounds that bind intronic regions of mRNA encoding sFLT1 protein, thereby inhibiting expression of sFLT1 protein for treatment of preeclampsia and other angiogenic disorders. Targeting these regions with RNAi compounds enables selective silencing of truncated, soluble variants without interfering with regular FLT1 function. Further, there is no detectable transfer of the oligonucleotides to the fetus.
Title: Transgenic Expression of DnaseI in vivo Delivered by an Adeno-associated Virus Vector. UMMS15-38; Patent Pending.
This invention uses AAV therapy to deliver an important enzyme, DNaseI, for cyctic fibrosis (CF) treatment. Traditional clinical methods of DnaseI delivery use solely nebulizers, which limit the delivery of the enzyme to the lung. With this new quality-controlled AAV vector for delivery, DnaseI can now be delivered locally to other organ systems affected by CF for more comprehensive disease management.
Title: Creation of RIPK3 Reporter and Conditional Deletion Mouse Model. UMMS15-05; Patent Pending.
This invention allows investigators to track endogenous RIPK3 expression in live cells and enables tissue-specific inactivation of RIPK3. Specifically, the last coding exon of the mouse RIPK3 gene is fused in-frame to the enhanced green fluorescent protein (GFP). LoxP sites flank the last coding exon of RIPK3. Crossing the RIPK3-GFP “floxed” mice to transgenic mice expressing Cre recombinase under the control of tissue-specific promoter enables conditional deletion and inactivation of RIPK3 in distinct tissues.
Title: System and Method for Using Somatic Movement to Improve Prediction and Prevention of Infant Apnea. UMMS13-75; Patent Pending.
The present invention relates to methods and systems for inhibiting apneic and hypoxic events. More specifically, the present invention provides methods for monitoring physiological signals of a patient, predicting the occurrence of a life-threatening event such as apnea or hypoxia, and initiating a stimulus to lessen the severity of, or even prevent, the occurrence of the life-threatening event.
Title: Monoclonal Antibodies to sFlt1 and Uses Thereof. UMMS13-51; Patent Pending.
This technology discloses novel antibodies and antibody fragments that bind soluble fms-like tyrosine kinase 1 (sFlt1) in an isoform specific manner. Further disclosed are assays employing sFlt1 antibodies to evaluate preeclampsia in pregnant women.
Title: Decide2Quit.org. UMMS12-06; Patent Pending.
A web-based system for implementing a smoking cessation support therapy that promotes individual, proactive participation by obtaining an initial consent, indicating motivation, from a patient, and linking the patient with a clinician for monitoring, feedback, and direction of subsequent support media based on clinician oversight and the reported motivation of the patient. The disclosed system encompassing self-motivation assessment, reinforcement feedback, and communication linkages to both clinicians and peers provides for a proactive response by a patient to a clinician invitation, thus establishing a minimal motivational level, and gathers statistical and motivational information from the patient for subsequent monitoring by the clinician.